A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata
Sponsor: Sanofi
A PHASE2 clinical study on Alopecia Areata, this trial is ongoing. The trial is conducted by Sanofi and has accumulated 8 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Augsburg, Germany , Barcelona, Spain , Berlin, Germany , Birmingham, United States , Bologna, Italy , Brest, France , Buenos Aires, Argentina , Calgary, Canada , Charlotte, United States and 52 more locations